Eisai Closes Door on Lorcaserin Program for Dravet Syndrome
Eisai has discontinued 2 clinical trials for lorcaserin in Dravet syndrome due to recruitment challenges in this rare epilepsy. The affected trials include the phase 3 MOMENTUM 1 study (NCT04572243) and MOMENTUM 2 extended access program, as first reported …